AZD8421 for Breast and Ovarian Cancer
(CYCAD-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug, AZD8421, alone and with other cancer drugs in patients with advanced breast and ovarian cancer who haven't responded well to standard treatments. The goal is to see if it is safe and effective in controlling cancer growth.
Do I have to stop taking my current medications for the trial?
You may need to stop taking certain medications before joining the trial. Specifically, you cannot take any drugs that strongly affect liver enzymes (CYP3A4/5) or have a risk of causing heart rhythm problems (Torsades de Pointes). It's best to discuss your current medications with the trial team to see if any need to be stopped.
Is AZD8421 (Camizestrant) safe for use in humans?
The safety data for CDK4/6 inhibitors like abemaciclib, which is similar to AZD8421, shows that they are generally well-tolerated in humans. Common side effects include diarrhea, infections, and neutropenia (low white blood cell count), but these are manageable. Patient quality of life is maintained during treatment.12345
What makes the drug AZD8421 unique for treating breast and ovarian cancer?
AZD8421 is unique because it combines a new treatment with existing CDK4/6 inhibitors like abemaciclib, which are known to help control cancer cell growth by targeting specific proteins involved in cell division. This combination could potentially offer a more effective approach for patients with breast and ovarian cancer, especially those who have not responded well to other treatments.678910
What data supports the effectiveness of the drug AZD8421 for breast and ovarian cancer?
Research shows that CDK4/6 inhibitors like abemaciclib, ribociclib, and palbociclib, when combined with endocrine therapy, significantly improve progression-free survival in hormone receptor-positive breast cancer. These drugs are now a standard treatment for this type of cancer, suggesting potential effectiveness for similar treatments like AZD8421.68111213
Who Is on the Research Team?
Richard Baird, MD, PhD
Principal Investigator
Cambridge University Hospitals
Are You a Good Fit for This Trial?
This trial is for adults with advanced breast cancer that's ER+HER2- or metastatic high-grade serious ovarian cancer. Participants must have measurable disease and be able to swallow pills. They should not have had certain treatments before, and their body should be functioning well enough to handle the study drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AZD8421 alone or in combination with selected targeted anti-cancer drugs to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- AZD8421
- Camizestrant
- CDK4/6 Inhibitor
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology